Baltic Conference of Hematology 2018
Programme
Invited Speakers
Harald HolteTatyana Ionova
Anna Porwit
Tadeusz Robak
Martin Hutchings
Steven Treon
Ewa Kimby
Mervi Taskinen
Karin Mellgren
Evangelos Terpos
Topics of the 11th Baltic Conference of Hematology :
- Acute lymphoblastic leukemia
- Hodgkin’s lymphoma
- Non-Hodgkin’s lymphoma
- Chronic lymphocytic leukemia
- Waldenström’s macroglobulinemia
- Myeloma
Friday, 19 October
| 12:00-14:00 | Registration Open |
| 14:00-15:00 | Congress Opening Ceremony. European Hematology Association (EHA)- Estonian Society of Hematology Joint Session |
| 15:00-15:45 | Chair: Kadri Saks Sanofi satellite session: Application of Next-Generation Sequencing (NGS)-based genetic screenings to hematologic disease: the case of lysosomal storage disorders and their differential diagnoses - Francisco J.del Castillo |
| 15:45-16:00 | Coffee break |
| 16:00-17:30 | Session I - ALL
Chair: Kadri Saks, Mari Punab 16:00-16:30 Update on Minimal Residual Disease in ALL - Anna Porwit 16:30-17:00 New trends in ALL therapy: what is changing with ALLTogether - Mervi Taskinen 17:00-17:15 Acute de novo lymphoblastic leukemia in adults in Estonia during 2007-2017: incidence, treatment modalities and survival - Mari Punab 17:15-17:30 Cytokine receptor and kinase signaling pathway activating alterations in pediatric and adult B-other ALL - Rimvydas Norvilas 17:30-17:45 Acute lymphoblastic leukemia (ALL) in Estonian children from 2008 to 2018: 10 year treatment results with NOPHO ALL-2008 protocol - Maarja Karu |
| 17:45-18:30 | Chair: Mariken Ross Pfizer Satellite session: Antibody directed approached in acute lymphoid leukemias - David Marks Invitation to Pfizer Satellite Session in PDF-format. |
| 20:00-22:00 | Welcome reception at Seaplane Harbor of Maritime Museum, Vesilennuki tee 6, Tallinn. Transfer to the reception venue will leave 19:45 infront of Radisson Blu Sky Hotel. Transfer back to hotel will leave at 22:00 |
Saturday, 20 October
| 08:00-09:30 |
II session: CLL/ hematological malignancies Chair: Iige Viigimaa, Sandra Lejniece 08:00-8:30 CLL: an update with focus on conventional therapy Eva Kimby 08:30-9:00 Current diagnostic and therapeutic recommendations for CLL - Tadeusz Robak 9:00-9:15 First results of Venetoclax in combination with low dose Cytarabine or Actinomycin D in relapsed/refractory acute leukemia patients - Andrius Zucenka 09:15-9:30 Time from symptom onset to diagnosis and treatment among hematological malignancies: influencing factors and associated negative outcomes - Austeja Dapkeviciute |
| 09:30-09:45 | Coffee break |
| 09:45-11:15 |
Session III - Lymphoma I Chair: Ugne Ringeleviciute, Hele Everaus 09:45-10:15 CAR019 therapy in relapsed Diffuse large B-cell lymphomas: Experience from an international multicenter study - Harald Holte 10:15-10:45 Children's non-Hodgkin lymphoma – actual status of treatment studies in the European Intergroup - Karin Mellgren 10:45-11:00 Epidemiology and treatment of HIV-associated lymphomas in Estonia - Iige Viigimaa 11:00-11:15 The spectrum of lymphoproliferative diseases in Lithuania 2010-2016: how are we different from the west? - Ugne Ringeleviciute |
| 11:15-11:30 | Coffee break |
| 11:30-13:05 |
IV sessioon: Plasma Cell disorders, including Waldenström's Macroglobulinemia Chair:Valdas Peceliunas, Evangelos Terpos 11:30-12:00 Genomic and Treatment Advances in Waldenstrom’s Macroglobulinemia - Steven Treon 12:00-12:30 Optimal sequencing of treatment for ASCT non eligible patients - Evangelos Terpos 12:30-12:45 Genomic Instability in Multiple Myeloma - Edward Laane 12:45-13:05 Systems Medicine Approach for Individualized Management of Lymphoproliferative Malignancies-a Novel Way for the Progress? - Hele Everaus |
| 13:05-14:00 | Lunch |
| 14:00-15:00 | Chair:Iige Viigimaa Janssen satellit session: Clinical Approach to Patients with High Molecular Risk Chronic Lymphocytic Leukemia - Davide Rossi |
| 15:05-17:00 | V sessioon: Lymfoma II Chair:Edward Laane, Ilze Trociukas 15:05-15:35 1st line and PET-response adapted treatment in Hodgkin's lymphoma - Martin Hutchings 15:35-16:05 Treatment of relapsed/refractory Hodgkin's lymphoma - Martin Hutchings 16:05-16:35 Assessing patient-reported outcomes in lymphoma patients: why, when and how. - Tatyana Ionova 16:35-16:50 B follicular lymphoma in Lithuania 2008-2017: incidence, evolution, survival - Ugne Ringeleviciute 16:50-17:05 Brentuximab vedotin and nivolumab in relapsed/refractory Hodgkin lymphoma: Estonian experience - Julia Abubikirova |
| 17:05-17:20 | Conclusions from the day |